

## References QBRI Insights: Forerunners in the vaccine race against SARS-CoV-2

- 1. Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ [Internet]. 2020 Nov 17 [cited 2020 Dec 9];371:m4471. Available from: http://dx.doi.org/10.1136/bmj.m4471
- 2. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints | Pfizer [Internet]. [cited 2020 Dec 9]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
- 3. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science (80-) [Internet]. 1990 [cited 2020 Dec 9];247(4949):1465–8. Available from: https://pubmed.ncbi.nlm.nih.gov/1690918/
- 4. Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro tats: Intrahypothalamic injection of vasopressin mRNA. Science (80-) [Internet]. 1992 [cited 2020 Dec 9];255(5047):996–8. Available from: https://pubmed.ncbi.nlm.nih.gov/1546298/
- 5. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines-a new era in vaccinology [Internet]. Vol. 17, Nature Reviews Drug Discovery. Nature Publishing Group; 2018 [cited 2020 Dec 8]. p. 261–79. Available from: /pmc/articles/PMC5906799/?report=abstract
- 6. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases [Internet]. Vol. 10, Frontiers in Immunology. Frontiers Media S.A.; 2019 [cited 2020 Dec 9]. p. 594. Available from: www.frontiersin.org
- 7. Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R. mRNA cancer vaccines. In: Recent Results in Cancer Research [Internet]. Springer New York LLC; 2016 [cited 2020 Dec 8]. p. 61–85. Available from: https://pubmed.ncbi.nlm.nih.gov/28101688/
- 8. Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. medRxiv Prepr Serv Heal Sci [Internet]. 2020 Aug 20 [cited 2020 Dec 10]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32839784
- 9. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 Preliminary Report. N Engl J Med. 2020 Nov 12;383(20):1920–31.
- 10. mRNA Science and Function: What Does mRNA Do? Moderna [Internet]. [cited 2020 Dec 10]. Available from: https://www.modernatx.com/mrna-technology/science-and-fundamentals-mrna-technology

P.O. Box: 34110 Doha - Qatar Tel: +974 4454 7152 Fax: +974 4454 1770 ص.ب: ۳٤۱۱۰ الدوحة - قطر هاتف: ۷۱۵۲ ع۵۶۵ ۹۷۴+ فاکس: ۷۷۷ ع8۶۵ ۹۷۲+



- 11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec 10 [cited 2020 Dec 14];NEJMoa2034577. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2034577
- 12. Rubin EJ, Longo DL. SARS-CoV-2 Vaccination An Ounce (Actually, Much Less) of Prevention. N Engl J Med [Internet]. 2020 Dec 10 [cited 2020 Dec 14];NEJMe2034717. Available from: http://www.nejm.org/doi/10.1056/NEJMe2034717
- 13. Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | Pfizer [Internet]. [cited 2020 Dec 14]. Available from: https://www.pfizer.com/news/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
- 14. Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc. [Internet]. [cited 2020 Dec 14]. Available from: https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy
- 15. Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19 | Pfizer [Internet]. [cited 2020 Dec 10]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world
- 16. Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19 | Pfizer [Internet]. [cited 2020 Dec 10]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-share-positive-early-data-lead-mrna
- 17. Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ [Internet]. 2020 Nov 17 [cited 2020 Dec 10];371:m4471. Available from: http://dx.doi.org/10.1136/bmj.m4471